Endometrial Cancer Trial, Recruiting NCT07220512 Sponsor: Wake Forest University Health Sciences Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT07220512
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are able to understand the study and are willing to sign a consent form approved by an ethics board.
  • You are over 55 years old at the time of joining the study.
  • You have been newly diagnosed with a suspected cancer of the ovaries, the lining of the abdomen (peritoneum), or the fallopian tubes at an advanced stage (Stage II–IV), OR a newly diagnosed suspected cancer of the uterus (endometrial cancer) at an advanced stage (Stage II–IV).
  • You are planned to receive 3 or 4 cycles of chemotherapy before surgery (called neoadjuvant chemotherapy), with surgery planned afterwards to remove as much cancer as possible.
  • You are able to read, understand, and write in English.
  • You are able to understand and follow the study procedures for the full length of the study, as decided by the doctor running the trial.

Who may not be able to join:

  • You have a history of cancer that has spread to the brain.
  • You have a history of serious mental health conditions that required a hospital stay in the last 3 months, or a history of brain injury, stroke, or dementia.
  • You are currently taking certain medications that affect the brain, including anti-amyloid drugs, cholinesterase inhibitors, or glutamate regulators (confirm with trial site if you are unsure whether your medications fall into these categories).
  • You have a vision problem that would make it difficult to complete the study assessments, as decided by the doctor running the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Anna Kuan-Celarier, MD, Wake Forest University Health Sciences

Phone: 336-713-5879

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
28 July 2025
Est. completion
1 November 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in electronic frailty index (eFI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov